These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15187052)

  • 21. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Dorey FJ; Walsh PC; Partin AW
    JAMA; 2005 Jul; 294(4):433-9. PubMed ID: 16046649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer.
    Stattin P; Bergh A; Karlberg L; Tavelin B; Damber JE
    Eur Urol; 1997; 32(4):404-9. PubMed ID: 9412796
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
    Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
    Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural history of localised prostatic cancer. A population-based study in 223 untreated patients.
    Johansson JE; Adami HO; Andersson SO; Bergström R; Krusemo UB; Kraaz W
    Lancet; 1989 Apr; 1(8642):799-803. PubMed ID: 2564901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The 20-Yr outcome in patients with well- or moderately differentiated clinically localized prostate cancer diagnosed in the pre-PSA era: the prognostic value of tumour ploidy and comorbidity.
    Adolfsson J; Tribukait B; Levitt S
    Eur Urol; 2007 Oct; 52(4):1028-35. PubMed ID: 17467883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The natural course of untreated, localized primary prostate carcinoma].
    Johansson JE
    Urologe A; 1996 Nov; 35(6):446-8. PubMed ID: 9064880
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
    Thompson IM; Tangen CM; Paradelo J; Lucia MS; Miller G; Troyer D; Messing E; Forman J; Chin J; Swanson G; Canby-Hagino E; Crawford ED
    JAMA; 2006 Nov; 296(19):2329-35. PubMed ID: 17105795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Prostate cancer screening (III): risk factors, natural history, course without treatment. Characteristics of detected cancers].
    Villers A; Soulié M; Haillot O; Boccon-Gibod L
    Prog Urol; 1997 Sep; 7(4):655-61. PubMed ID: 9410329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D; Lindner A; Stay K; Zisman A
    Harefuah; 2006 Oct; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Natural course of localized prostate cancer. a personal view with a review of published papers.
    Hugosson J; Aus G
    Anticancer Res; 1997; 17(3A):1441-8. PubMed ID: 9179181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer.
    Messing EM; Manola J; Sarosdy M; Wilding G; Crawford ED; Trump D
    N Engl J Med; 1999 Dec; 341(24):1781-8. PubMed ID: 10588962
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Results of 15 years of radical prostatectomy].
    Frohmüller H; Theiss M; Wirth M; Hofmockel G
    Urologe A; 1995 May; 34(3):225-30. PubMed ID: 7610518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Active surveillance with selective delayed intervention: walking the line between overtreatment for indolent disease and undertreatment for aggressive disease.
    Klotz LH
    Can J Urol; 2005 Feb; 12 Suppl 1():53-7; discussion 101-2. PubMed ID: 15780167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H; Lau W; Bergstralh E; Blute ML
    J Urol; 2001 Dec; 166(6):2208-15. PubMed ID: 11696737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
    Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
    Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.